COVID-19 outcome in leukemic patients: a cross-sectional study
Medical Journal of Tabriz University of Medical Sciences · 23.12.2025 · 47 (5) · 549-559
DOI: 10.34172/mj.025.34045 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Medical Journal of Tabriz University of Medical Sciences, online erschienen am 09.11.2025. Verfasst von Mardani Masoud und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Predicting the severity of the COVID-19 infection in patients with leukemia would be helpful in the proper management of the infection in these patients. In this regard, this study aimed to identify predictive biomarkers in leukemic patients diagnosed with COVID-19.
Methods
In this retrospective cross-sectional study, the data of 173 leukemic patients who were diagnosed with COVID-19 were used. These patients were admitted to Taleghani Hospital in Tehran, Iran, from March 2020 to September 2022.
Results
The mean age of patients was 52.1±16.8, ranging from 14 to 87 years. Most of them had AML (35.1%), and CKD (19.1%) was the most prevalent underlying disease among them. The mean time of hospitalization was 16.8 days, and 46.8% of leukemia patients with COVID-19 died during hospitalization. The mean level of AST (157.3±82, P
Zitieren
APA
Masoud, M., Jafar, M., Amir, T., & Roghayeh, T. (2025). COVID-19 outcome in leukemic patients: a cross-sectional study. Medical Journal of Tabriz University of Medical Sciences, 47(5), 549-559. https://doi.org/10.34172/mj.025.34045
Vancouver
Masoud M, Jafar M, Amir T, Roghayeh T. COVID-19 outcome in leukemic patients: a cross-sectional study. Medical Journal of Tabriz University of Medical Sciences. 2025;47(5):549-559. doi:10.34172/mj.025.34045
BibTeX
@article{Masoud2025,
author = {Masoud, Mardani and Jafar, Mohammadshahi and Amir, Teimourpour and Roghayeh, Teimourpour},
title = {COVID-19 outcome in leukemic patients: a cross-sectional study},
journal = {Medical Journal of Tabriz University of Medical Sciences},
year = {2025},
volume = {47},
number = {5},
pages = {549--559},
doi = {10.34172/mj.025.34045}
}
EUVIMED